Segall Bryant & Hamill LLC Cuts Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Segall Bryant & Hamill LLC cut its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 4.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,422,196 shares of the biotechnology company's stock after selling 68,180 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.69% of BioCryst Pharmaceuticals worth $10,695,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in BCRX. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $46,000. R Squared Ltd purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter valued at $48,000. KBC Group NV grew its holdings in shares of BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after buying an additional 4,537 shares during the last quarter. Raymond James Financial Inc. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth $80,000. Finally, Quantinno Capital Management LP purchased a new position in BioCryst Pharmaceuticals in the 3rd quarter worth $82,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX traded down $0.36 during trading hours on Monday, hitting $7.50. The stock had a trading volume of 2,216,032 shares, compared to its average volume of 2,789,809. The firm has a 50-day moving average price of $8.18 and a 200 day moving average price of $7.82. BioCryst Pharmaceuticals, Inc. has a fifty-two week low of $4.03 and a fifty-two week high of $9.50. The firm has a market capitalization of $1.57 billion, a price-to-earnings ratio of -12.29 and a beta of 1.85.

Remove Ads

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the prior year, the business posted $0.28 EPS. The business's revenue for the quarter was up 40.8% on a year-over-year basis. As a group, analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the company. JMP Securities reissued a "market outperform" rating and issued a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target on the stock. Needham & Company LLC lifted their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, January 13th. Evercore ISI upped their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.